IP Verse

Ipsen Biopharm Ltd. competitive analysis

Latest patents of Ipsen Biopharm Ltd. opposed by its competitors

Explore Ipsen Biopharm Ltd.'s recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3362049
Jul 9, 2025Stabilizing Camptothecin Pharmaceutical Compositions2
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer3
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment1
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin2
EP2861210
May 3, 2017Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan1

Latest PTAB cases involving Ipsen Biopharm Ltd.

Discover the latest PTAB cases involving Ipsen Biopharm Ltd., highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 27, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ipsen Biopharm Ltd.

IPR2025-00505Jan 17, 2025CSPC PHARMACEUTICAL GROUPIPSEN BIOPHARMFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Ipsen Biopharm Ltd. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
IPSEN BIOPHARM112 - 2
GENERICS UK226 - - -
SANDOZ1321919 -
TEVA PHARMACEUTICAL INDUSTRIES LTD2094 - -